Clinical Trial Update: Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial assessing AFQ056 for safety, tolerability, and efficacy in Parkinson's patients with L-dopa induced dyskinesias completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia Drug-induced
• Levodopa
• Parkinson Disease

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 | Status: COMPLETED